Sponsors of the 2018 ANZSN ASM will be recognised as keen and vital supporters of the field. Profiles of the 2018 ASM sponsors are listed below. To find out more about how you can be involved visit the Sponsorship & Exhibition Opportunities page.
To become a Platinum, Gold, Silver or Bronze ANZSN Society sponsor please contact Jourdan at the secretariat email@example.com.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
UPDATE COURSE SPONSOR
Amgen is also the proud sponsor of the General Nephrology theme for the Nephrology and Transplantation Update Course held 8th – 9th September prior to the main ASM. View the program here.
Fresenius Medical Care, The Renal Company, is the world’s largest intergraded manufacturer and provider of products, therapies and services for renal patients.
We care for nearly 310,000 patients in our global network of more than 3,600 dialysis clinics. At the same time, we operate 37 production sites on all continents, to provide dialysis products such as dialysis machines, dialysers, PD fluids and related disposables.
As the largest provider of dialysis care in Australia, we intimately understand the impact chronic kidney failure has on people’s lives. We are committed to delivering outstanding patient care that goes beyond innovative dialysis products and therapies. We care for each individual patients situation, whether they wish to perform dialysis at home or receive dialysis within one of our 18 clinics across the country. Our ability to deliver excellent patient outcomes is due to the quality and professionalism of over 350 full and part time nursing staff we employ across Australia, who provide dialysis to around 800 patients. Our nursing teams share our passion for creating a future worth living for every one of our patients.
For nearly half a century we have been helping patients with end stage renal disease live fuller, richer and more active lives. We are committed to life, to life-changing outcomes, everything renal.
Sanofi, a world leader in Life Science, committed to prevention and treatment of disease and to supporting populations throughout the world.
We are Sanofi, we live for life. By partnering with patients we can find new ways of helping them feel better, live longer, keep healthy and stay stronger.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Twentynine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines.
Founded in 1896, the Roche Group is headquartered in Basel, Switzerland, and is active in over 100 countries. In 2016 Roche employed more than 94,00 people worldwide and invested CHF 9.9 billion in research and development, including almost AUD 37 million in pharmaceuticals in Australia.
Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
Roche’s pharmaceutical division in Australia is dedicated to the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines. Australian patients have access to about 40 Roche medicines, and the company is the leading provider of cancer medicines in
Australia by sales.
Astellas Pharma Australia Pty Ltd is part of Astellas Pharma Inc., a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. Its focus is on Nephrology, Urology, Oncology, Immunology, and Neuroscience as prioritised therapeutic areas while advancing new treatments through discovery research. Young and forward thinking, Astellas is dedicated to improving the lives of people with our ethos of CHANGING TOMMORROW®. We are a pioneer in the field of transplantation and for over 20 years have worked alongside both health care professionals and the transplant and nephrology communities as an active and trusted partner.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. We have more than 60 years’ history in Australia and employ around 800 associates across our three divisions. We believe continued R&D is essential to innovation and in Australia we invest around 20M annually in local clinical trials. Our mission is to discover new ways to improve and extend people’s lives.
To find out more about Novartis in Australia visit the website:
UPDATE COURSE SPONSOR
Novartis is also the proud sponsor of the Transplantation theme for the Nephrology and Transplantation Update Course held 8th – 9th September prior to the main ASM. View the program here.
Baxter’s Renal business is committed to addressing the individual needs of end-stage renal disease (ESRD) patients by providing access to innovative products, therapies, services and support designed to improve their health-related, quality-of-life. Baxter has 125 collective years of experience in renal care. The company continues to invest in the business, reflecting its commitment to advancing and simplifying dialysis, expanding capacity for growing demand and investing in R&D to drive innovation.
UPDATE COURSE SPONSOR
Baxter is also the proud sponsor of the Dialysis theme for the Nephrology and Transplantation Update Course held 8th – 9th September prior to the main ASM. View the program here.
Alexion is focused on providing innovative treatments to patients with life-threatening rare diseases for which there are few, if any, effective treatment options. Alexion established operations in Sydney in 2008 to serve patients in the Australia and Asia region. We aim to work in partnership with all stakeholders including healthcare providers, patient advocacy organisations and government in order to best serve patients. By expanding the knowledge and awareness of rare diseases, we help the medical community improve the process for diagnosis and treatment. Our goal is to bring hope to patients and families by delivering life-changing therapies.